By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Development and commercialization of icosapent ethyl (VASCEPA)213.65M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
US product revenue, net154.14M72.15%
Licensing and royalty revenue30.89M14.46%
Europe product revenue, net18.37M8.60%
Rest of World (RoW) product revenue, net10.24M4.79%